UTHR vs. RETA, BPMC, TEVA, BBIO, BIIB, ALNY, BMRN, NBIX, INCY, and RGEN
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Reata Pharmaceuticals (RETA), Blueprint Medicines (BPMC), Teva Pharmaceutical Industries (TEVA), BridgeBio Pharma (BBIO), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), and Repligen (RGEN). These companies are all part of the "medical" sector.
United Therapeutics (NASDAQ:UTHR) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings.
United Therapeutics has higher revenue and earnings than Reata Pharmaceuticals.
United Therapeutics presently has a consensus target price of $309.44, indicating a potential upside of 12.47%. Reata Pharmaceuticals has a consensus target price of $162.44, indicating a potential downside of 5.75%. Given United Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe United Therapeutics is more favorable than Reata Pharmaceuticals.
United Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
In the previous week, United Therapeutics had 11 more articles in the media than Reata Pharmaceuticals. MarketBeat recorded 11 mentions for United Therapeutics and 0 mentions for Reata Pharmaceuticals. United Therapeutics' average media sentiment score of 0.77 beat Reata Pharmaceuticals' score of 0.00 indicating that United Therapeutics is being referred to more favorably in the media.
94.1% of United Therapeutics shares are held by institutional investors. 12.5% of United Therapeutics shares are held by insiders. Comparatively, 26.8% of Reata Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
United Therapeutics received 227 more outperform votes than Reata Pharmaceuticals when rated by MarketBeat users. Likewise, 61.80% of users gave United Therapeutics an outperform vote while only 60.35% of users gave Reata Pharmaceuticals an outperform vote.
United Therapeutics has a net margin of 42.05% compared to Reata Pharmaceuticals' net margin of 0.00%. United Therapeutics' return on equity of 18.72% beat Reata Pharmaceuticals' return on equity.
Summary
United Therapeutics beats Reata Pharmaceuticals on 13 of the 16 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
